Maraviroc Formula: C29H41F2N5O
Maraviroc is an entry inhibitor. Specifically, maraviroc is a negative allosteric modulator of the CCR5 receptor, which is found on the surface of certain human cells. The chemokine receptor CCR5 is an essential co-receptor for most HIV strains and necessary for the entry process of the virus into the host cell. The drug binds to CCR5, thereby blocking the HIV protein gp120 from associating with the receptor. HIV is then unable to enter humanmacrophages and T-cells. Because HIV can also use other coreceptors, such as CXCR4, an HIV tropism test such as a trofile assay must be performed to determine if the drug will be effective.
Development and approval
- Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK (April 2008). “Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects”. British Journal of Clinical Pharmacology 65 (Suppl 1): 60–7. doi:10.1111/j.1365-2125.2008.03137.x. PMC 2311408. PMID 18333867.
- Abel S, Back DJ, Vourvahis M (2009). “Maraviroc: pharmacokinetics and drug interactions”. Antiviral Therapy 14 (5): 607–18. PMID 19704163.
- Blocade of lymphocyte chemotaxis in visceral graft-versus-host disease, Ran Reshef et al., New England Journal of Medicine, 367:135 (July 12, 2012)
- Levy JA (January 2009). “HIV pathogenesis: 25 years of progress and persistent challenges”. AIDS 23 (2): 147–60. doi:10.1097/QAD.0b013e3283217f9f. PMID 19098484.
- Biswas P, Tambussi G, Lazzarin A (May 2007). “Access denied? The status of co-receptor inhibition to counter HIV entry”. Expert Opinion on Pharmacotherapy 8 (7): 923–33.doi:10.1517/146565220.127.116.113. PMID 17472538.
- Gay News From 365Gay.com
- Krauskopf, Lewis (August 6, 2007). “Pfizer wins U.S. approval for new HIV drug”. Reuters. Retrieved 2007-08-06.
- Reuters, Europe gives final approval to Pfizer HIV drug
- ^ Jump up to:a b Stephenson J (April 2007). “Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus”. JAMA 297 (14): 1535–6. doi:10.1001/jama.297.14.1535.PMID 17426263.
- Emmelkamp JM, Rockstroh JK (October 2007). “CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions–review of the literature”. European Journal of Medical Research 12 (9): 409–17. PMID 17933722.
- ”Maraviroc reduces viral load in naive patients at 48 weeks”. AIDS Patient Care and STDs 21 (9): 703–4. September 2007. PMID 17941136.
- BBC News story: Drug ‘stops HIV’s entry to cells’
- Maraviroc data at aidsmap
- Maraviroc early access program
- New HIV Drug Recommended for Approval
- maraviroc at the US National Library of Medicine Medical Subject Headings (MeSH)